Nerviano Medical Sciences Announces a New Collaboration Agreement With Genentech to Discover Antibody Drug Conjugates



    NERVIANO, Italy, Oct. 21 /CNW/ - Nerviano Medical Sciences (NMS), the
largest pharmaceutical R&D facility in Italy and one of the leading
oncology-focused, integrated discovery and development companies in Europe,
today announced a new multi-year agreement with Genentech, Inc.
    This new research agreement is the second collaboration agreement signed
between Genentech and NMS in less than twelve months.
    The two Companies will collaborate in the discovery of antibody drug
conjugates for the development of potential anticancer agents.
    Genentech, which is a leading oncology company in the United States, will
have the exclusive license to fully develop and commercialize licensed
products that contain such antibody drug conjugates.
    During the research program, NMS will be primarily responsible for
synthesizing and manufacturing drug reagents, while Genentech will generate
antibody drug conjugates with such drug reagents and further evaluate their
potential therapeutic utility.
    Terms of the multi-year collaboration include an initial
one-time-license-fee, milestones and royalties for licensed products as well
as milestones on a target-by-target basis. Further details and financial terms
were not disclosed.
    "This new agreement marks an additional achievement in our strategic
alliances strategy and we are very excited about the prospect of expanding our
collaboration with Genentech one of the world's leading biotech companies,"
said Umberto Rosa, President of Nerviano Medical Sciences. "We believe that by
working together and applying our complementary world class research
capabilities in biologics and in small molecules, we may develop innovative
targeted products for patients suffering from cancer."
    "With this new collaboration we are very pleased to enhance our
collaboration with Genentech and to extend it in the field of antibody drug
conjugates, an area where biologics and small molecules meet to generate very
potent targeted therapies," added Giampiero Duglio, CEO of NMS. "I believe
that Nerviano's expertise in the discovery of potent small molecules may
contribute to innovative and valuable products for the oncology market."
    Nerviano Medical Sciences (http://www.nervianoms.com)
    Nerviano Medical Sciences is the largest R&D cancer drug stand alone
Company in Europe wholly owned by the Rome-based Congregazione dei Figli
dell'Immacolata Concezione.
    NMS leverages on strategic alliances with biotechnology and
pharmaceutical companies for the discovery and development of innovative
cancer therapies for securing long-term sustainability of the business.
    NMS has already in place collaborations with Genentech Inc. and other
major pharmaceutical companies such as Pfizer Inc. and BMS Co. as well as with
biotech- companies and academia.




For further information:

For further information: Nerviano Medical Sciences, Maria D'Acquino,
Phone +39-0331-581013 - mobile +39-335-18-63-052, Email
maria.dacquino@nervianoms.com

Organization Profile

NERVIANO MEDICAL SCIENCES

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890